PROCEPT BioRobotics (NASDAQ:PRCT) Insider Pooja Sharma Sells 4,710 Shares of Company Stock

Posted by George Bondi on Nov 7th, 2026

PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) insider Pooja Sharma sold 4,710 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $19.71, for a total transaction of $92,834.10. Following the completion of the sale, the insider directly owned 106,471 shares of the company’s stock, valued at $2,098,543.41. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock traded up $0.35 on Friday, reaching $20.62. The company’s stock had a trading volume of 1,850,317 shares, compared to its average volume of 1,113,616. The stock’s 50 day simple moving average is $19.32 and its 200-day simple moving average is $23.13. PROCEPT BioRobotics Corporation has a 12-month low of $16.67 and a 12-month high of $38.11. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.18 billion, a P/E ratio of -10.21 and a beta of 0.88.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $98.29 million for the quarter, compared to the consensus estimate of $100.52 million. During the same quarter in the prior year, the company earned ($0.38) EPS. PROCEPT BioRobotics’s revenue was up 18.0% compared to the same quarter last year. As a group, equities analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PRCT has been the subject of a number of recent analyst reports. TD Cowen decreased their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a report on Wednesday, August 5th. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Leerink Partners increased their price target on shares of PROCEPT BioRobotics from $20.00 to $22.00 and gave the company a “market perform” rating in a report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Hold” and an average price target of $25.25.

Check Out Our Latest Stock Report on PRCT

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Johnson & Johnson purchased a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $8,082,263. Bank of America Corp DE acquired a new position in shares of PROCEPT BioRobotics during the second quarter valued at approximately $11,656,000. Quantinno Capital Management LP purchased a new position in PROCEPT BioRobotics in the 1st quarter valued at $1,693,000. Corient Private Wealth LP acquired a new stake in PROCEPT BioRobotics during the 2nd quarter worth $2,448,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of PROCEPT BioRobotics during the second quarter worth $1,203,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.